NEW INDICATIONS! Sogroya^® is the first and only once-weekly growth hormone treatment approved for children 2.5 years of age and older who are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years, are not growing and have Noonan Syndrome (NS), and have Idiopathic Short Stature (ISS). Ask your doctor for more information. Please click here for Sogroya Prescribing Information.

Once-Weekly Sogroya^®

FREEDOM FROM DAILY INJECTIONS

Sogroya^® is the first once-weekly growth hormone treatment for children (2.5 years and older) and adults with growth hormone deficiency (GHD), and the first and only for children 2.5 years of age and older who are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years, are not growing and have Noonan Syndrome (NS), and have Idiopathic Short Stature (ISS).

Talk to your doctor about Sogroya^®: the most prescribed once-weekly GH treatment^a

Where would you like to go now? You can...

See long-term results & a safety profile for pediatric patients with GHD

Discover what a once-weekly GH treatment has to offer

View insurance: highest commercial preferred access for any long-acting GH treatment^b

Hear from families who chose to treat with Sogroya^®

^aBased on data from Komodo Sentinel as of February 2026.

^bCoverage status does not imply product endorsement.

Sogroya^®: 10 years of combined long-term exposure in pediatric GHD patients

Based on combined data from the REAL3, dose-finding, phase 2 trial, and REAL4 phase 3 trial in GHD pediatric patients.^c

^cREAL3 was a phase 2, randomized, open-label, dose-finding trial investigating the efficacy and safety of somapacitan vs daily GH in children with GHD. A total of 43 out of the 59 participants (aged 2.5 to 10 years) completed the long-term safety extension period (Week 364; Year 7), 10 of whom received daily GH from the start of the trial up to Week 156, and then switched to somapacitan 0.16 mg/kg/wk (switched group), and 33 of whom received somapacitan throughout the trial. REAL4 was a randomized, multi-national, open-label, active-controlled, parallel-group, phase 3 trial. The REAL4 main trial phase (Week 0 to Week 52) was followed by an ongoing 3-year, single-group, safety extension phase (Week 52 to  Week 208) featuring 194 patients of whom 188 completed 156 weeks of treatment.

The Sogroya^® pen: easy to use and based on the FlexPro^® you know^d

The Sogroya^® pen is ready to use, prefilled, and doesn’t require cartridges or preparation of the medicine. So, which device do you think is preferred by patients and caregivers alike?

^dIn a randomized, crossover device preference and handling study of the Sogroya^® pen in 33 adolescents aged 10-17 with growth-related disorders and 37 caregivers aged 18 and older, 99% (69) of participants found the Sogroya^® pen easy or very easy to use. After training, users performed simulated injections into a pad or mannequin and then completed the Device Handling and Preference Assessment Questionnaire (DHPAQ).

Let's grow!

Starting treatment or switching to Sogroya^®?

Sogroya^® has the highest commercial preferred access with an 91% approval rate among long-acting GH treatments.

The first once-weekly growth hormone (GH) treatment for children and adults with GHD, Sogroya^® has preferred coverage with CVS Caremark^®, Optum, FEP, TRICARE^®, Texas Medicaid, MedImpact/Elixir, and Aetna^®. Get more information about support programs as you begin your GH journey.^e

Get started

^eIndividual benefit designs and individual coverage may vary. Because many health plans offer more than one formulary, check directly with your health plan to confirm coverage.

Actor portrayal

Are you an adult living with AGHD?

Leave the once-daily baggage behind with Sogroya^®. The first once-weekly treatment for adult growth hormone deficiency (AGHD).

Learn more

Already on Sogroya^®?

Get help planning injections

The Sogroya^® Smart Scheduler will help you manage your injection days, including split doses.

Try it

Personalize your pen

Let’s make dose day more fun! With tons of charms and stickers to choose from, kids can express themselves with their pen.

Pick your charms

Updates and helpful information

Tips and suggestions

Support, including patient resources

Show more Show less

Important Safety Information

Do not use Sogroya^® if:

you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
you have cancer or other tumors
you are allergic to somapacitan-beco or any of the ingredients in Sogroya^®
your healthcare provider tells you that you have certain types of eye problems caused by diabetes
you are a child with closed bone growth plates
you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya^®, tell your healthcare provider about all of your medical conditions, including if you:

have had heart or stomach surgery, trauma, or serious breathing problems
have had cancer or any tumor
have diabetes
have adrenal gland problems
are taking replacement therapy with glucocorticoids
have thyroid gland problems
have liver problems
are a child with a history of worsening of curvature of the spine (scoliosis)
are pregnant or plan to become pregnant. It is not known if Sogroya^® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
are breastfeeding or plan to breastfeed. It is not known if Sogroya^® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya^® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya^® may affect the way some medicines work, and some medicines may affect how Sogroya^® works.

How should I use Sogroya^®?

Use Sogroya^® exactly as your healthcare provider tells you to
Use Sogroya^® 1 time each week
If you miss a dose of Sogroya^®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
Sogroya^® pens are for use by 1 person only
Do not share your Sogroya^® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya^®?

Sogroya^® may cause serious side effects, including:

high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya^®
increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya^® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya^®
worsening of curvature of the spine in children (scoliosis)
hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to lack of blood supply (osteonecrosis). Get medical help right away if your child develops a limp or has hip or knee pain
high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya^® in children include: cough, common cold, diarrhea, ear infection, headache, fever, pain in extremity, reaction to injection, respiratory tract infection, and vomiting

The most common side effects of Sogroya^® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), swelling in the feet and hands (peripheral edema), vomiting, low cortisol levels (adrenal insufficiency), high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya^® Prescribing Information.

Sogroya^® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Sogroya^®?

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya^® is given by injection under the skin (subcutaneous).
Sogroya^® is used to treat children 2.5 years of age and older who:
- are not growing because of low or no growth hormone
- are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
- are not growing and have Noonan Syndrome (NS)
- have Idiopathic Short Stature (ISS)
Sogroya^® is used to treat adults who do not make enough growth hormone

What is Sogroya^®?

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya^® is given by injection under the skin (subcutaneous).
Sogroya^® is used to treat children 2.5 years of age and older who:
- are not growing because of low or no growth hormone
- are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
- are not growing and have Noonan Syndrome (NS)
- have Idiopathic Short Stature (ISS)
Sogroya^® is used to treat adults who do not make enough growth hormone

Show more Show less

What is Sogroya^®?

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya^® is given by injection under the skin (subcutaneous).
Sogroya^® is used to treat children 2.5 years of age and older who:
- are not growing because of low or no growth hormone
- are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
- are not growing and have Noonan Syndrome (NS)
- have Idiopathic Short Stature (ISS)
Sogroya^® is used to treat adults who do not make enough growth hormone

What is Sogroya^®?

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya^® is given by injection under the skin (subcutaneous).
Sogroya^® is used to treat children 2.5 years of age and older who:
- are not growing because of low or no growth hormone
- are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
- are not growing and have Noonan Syndrome (NS)
- have Idiopathic Short Stature (ISS)
Sogroya^® is used to treat adults who do not make enough growth hormone

Important Safety Information

Do not use Sogroya^® if:

you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
you have cancer or other tumors
you are allergic to somapacitan-beco or any of the ingredients in Sogroya^®
your healthcare provider tells you that you have certain types of eye problems caused by diabetes
you are a child with closed bone growth plates
you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Important Safety Information

Do not use Sogroya^® if:

you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
you have cancer or other tumors
you are allergic to somapacitan-beco or any of the ingredients in Sogroya^®
your healthcare provider tells you that you have certain types of eye problems caused by diabetes
you are a child with closed bone growth plates
you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya^®, tell your healthcare provider about all of your medical conditions, including if you:

have had heart or stomach surgery, trauma, or serious breathing problems
have had cancer or any tumor
have diabetes
have adrenal gland problems
are taking replacement therapy with glucocorticoids
have thyroid gland problems
have liver problems
are a child with a history of worsening of curvature of the spine (scoliosis)
are pregnant or plan to become pregnant. It is not known if Sogroya^® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
are breastfeeding or plan to breastfeed. It is not known if Sogroya^® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya^® while you breastfeed

How should I use Sogroya^®?

Use Sogroya^® exactly as your healthcare provider tells you to
Use Sogroya^® 1 time each week
If you miss a dose of Sogroya^®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
Sogroya^® pens are for use by 1 person only
Do not share your Sogroya^® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya^®?

Sogroya^® may cause serious side effects, including:

high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya^®
increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya^® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya^®
worsening of curvature of the spine in children (scoliosis)
hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to lack of blood supply (osteonecrosis). Get medical help right away if your child develops a limp or has hip or knee pain
high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

Please click here for Sogroya^® Prescribing Information.

Sogroya^® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

Do not use Sogroya^® if:

you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
you have cancer or other tumors
you are allergic to somapacitan-beco or any of the ingredients in Sogroya^®
your healthcare provider tells you that you have certain types of eye problems caused by diabetes
you are a child with closed bone growth plates
you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya^®, tell your healthcare provider about all of your medical conditions, including if you:

have had heart or stomach surgery, trauma, or serious breathing problems
have had cancer or any tumor
have diabetes
have adrenal gland problems
are taking replacement therapy with glucocorticoids
have thyroid gland problems
have liver problems
are a child with a history of worsening of curvature of the spine (scoliosis)
are pregnant or plan to become pregnant. It is not known if Sogroya^® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
are breastfeeding or plan to breastfeed. It is not known if Sogroya^® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya^® while you breastfeed

How should I use Sogroya^®?

Use Sogroya^® exactly as your healthcare provider tells you to
Use Sogroya^® 1 time each week
If you miss a dose of Sogroya^®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
Sogroya^® pens are for use by 1 person only
Do not share your Sogroya^® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya^®?

Sogroya^® may cause serious side effects, including:

high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya^®
increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya^® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya^®
worsening of curvature of the spine in children (scoliosis)
hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to lack of blood supply (osteonecrosis). Get medical help right away if your child develops a limp or has hip or knee pain
high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

Please click here for Sogroya^® Prescribing Information.

Sogroya^® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Sogroya^®?

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya^® is given by injection under the skin (subcutaneous).
Sogroya^® is used to treat children 2.5 years of age and older who:
- are not growing because of low or no growth hormone
- are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
- are not growing and have Noonan Syndrome (NS)
- have Idiopathic Short Stature (ISS)
Sogroya^® is used to treat adults who do not make enough growth hormone

What is Sogroya^®?

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya^® is given by injection under the skin (subcutaneous).
Sogroya^® is used to treat children 2.5 years of age and older who:
- are not growing because of low or no growth hormone
- are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
- are not growing and have Noonan Syndrome (NS)
- have Idiopathic Short Stature (ISS)
Sogroya^® is used to treat adults who do not make enough growth hormone

Once-Weekly Sogroya®

Where would you like to go now? You can...

The Sogroya® pen: easy to use and based on the FlexPro® you knowd

Sogroya® has the highest commercial preferred access with an 91% approval rate among long-acting GH treatments.

Important Safety Information

Do not use Sogroya® if:

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

How should I use Sogroya®?

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

What is Sogroya®?

What is Sogroya®?

What is Sogroya®?

What is Sogroya®?

Important Safety Information

Do not use Sogroya® if:

Important Safety Information

Do not use Sogroya® if:

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

How should I use Sogroya®?

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

Important Safety Information

Do not use Sogroya® if:

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

How should I use Sogroya®?

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

What is Sogroya®?

What is Sogroya®?

Once-Weekly Sogroya^®

The Sogroya^® pen: easy to use and based on the FlexPro^® you know^d

Sogroya^® has the highest commercial preferred access with an 91% approval rate among long-acting GH treatments.

Do not use Sogroya^® if:

Before taking Sogroya^®, tell your healthcare provider about all of your medical conditions, including if you:

How should I use Sogroya^®?

What are the possible side effects of Sogroya^®?

Sogroya^® may cause serious side effects, including:

What is Sogroya^®?

What is Sogroya^®?

What is Sogroya^®?

What is Sogroya^®?

Do not use Sogroya^® if:

Do not use Sogroya^® if:

Before taking Sogroya^®, tell your healthcare provider about all of your medical conditions, including if you:

How should I use Sogroya^®?

What are the possible side effects of Sogroya^®?

Sogroya^® may cause serious side effects, including:

Do not use Sogroya^® if:

Before taking Sogroya^®, tell your healthcare provider about all of your medical conditions, including if you:

How should I use Sogroya^®?

What are the possible side effects of Sogroya^®?

Sogroya^® may cause serious side effects, including:

What is Sogroya^®?

What is Sogroya^®?